URACYST® For the Treatment of GAG Deficient Interstitial Cystitis

Inclusion Criteria: Patients must meet the following eligibility criteria in order to be enrolled in this study. Clinical diagnosis of interstitial cystitis Legally majority female capable and willing to provide informed consent Negative blood test for pregnancy at baseline or assurance of previous surgery, condition or state rendering conception impossible A sterile bacterial urine culture no more than thirty (30) days prior to first treatment An average urinary frequency of at least 11 times per 24-hour day An average pain/discomfort score of 4 or greater on a 0-10cm VAS scale Available for the duration of the study including treatment and follow-up (4 months) Exclusion Criteria: Pregnant or lactating Currently receiving or having received investigational drugs thirty (30) days or less prior to screening Currently receiving or having had prior therapy with intravesical treatment (eg. Uracyst, Cystistat®, heparin or BCG) Receiving therapy for less than three months with antidepressants, antihistaminics, hormonal agonists or antagonists; hence patient not stabilized on therapy. (Stable therapy defined as continuous treatment for at least three months.) Currently receiving or having received prior therapy with oral pentosanpolysulfate (Elmiron) 3 months or less prior to screening IC symptoms relieved by antimicrobials, anticholinergics or antispasmodics Bladder capacity of greater than 500 ml on awake cystometry using liquid filling medium Neurologic disease affecting bladder function; any previous surgery or procedure having affected bladder function Current urinary tract infection (must be treated and have a negative culture before study entry) Current diagnosis of chemical, tuberculous or radiation cystitis History of bladder or lower ureteral calculi History of cancer within the last five years other than adequately treated non-melanoma skin cancers Active sexual transmitted disease Current vaginitis Endometriosis Any condition/disease which in the opinion of the investigator could interfere with patient compliance and/ or interfere with the interpretation of the treatment results